Navigation Links
Dr. Douglas Harrington Speaks At The American Society for Preventive Cardiology Southeastern Conference 2013
Date:7/11/2013

IRVINE, Calif., July 11, 2013 /PRNewswire/ -- Aviir, Inc, a biotechnology company dedicated to the prevention of cardiovascular disease, today announced it will attend the Second Annual American Society for Preventive Cardiology Southeastern Conference 2013 in collaboration with Boca Raton Regional Hospital, along with their GUARDaHEART Foundation. The conference is focused on the prevention and treatment of cardiovascular disease in women.

(Logo:  http://photos.prnewswire.com/prnh/20130319/LA79677LOGO)

Heart Disease currently affects more than one in three women, and was responsible for the deaths of approximately 401,000 women in 2009 alone, accounting for 51% of total CVD related deaths. Since 1984, the number of female deaths associated with heart disease has been higher than those of the male population. Despite this, women remain undertreated for CVD.

Aviir's CEO and Laboratory Director, Dr. Douglas Harrington, will be giving a presentation entitled "Preventing Heart Disease: How Can Biomarker-Based Algorithms Complement Lipid Studies in Identifying Risk."

About Aviir
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next five years. Aviir's CLIA certified laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Aviir Inc., also offers testing across the molecular genetic spectrum, including pharmacogenetics, Leiden factor, and ApoE testing. Please visit www.aviir.com for more information.

About GUARDaHEART 
GUARDaHEART is a non-profit foundation dedicated to raising awareness of Heart Disease prevention by spreading the word to guard your heart and save your life. Cardiovascular disease is the leading cause of death in the United States. The good news is if individuals know their risk and take the necessary steps, most cardiovascular disease can be prevented and reversed if detected early. Although heart disease is typically diagnosed in adulthood, its roots are often found in childhood. Compelling research has shown that plaque buildup in the arterial walls begins very early in life and progresses throughout life. Intervention strategies and healthy lifestyle modification to reduce heart disease risk should begin early when reversal of the process is easier, not later in life when the disease is more developed. GUARDaHEART Foundation also provides assistance for individuals who are unable to pay for cardiac risk assessments. Please visit www.guardaheart.org for more information.

Company Contacts:
Matt Clawson
Life Capital Partners
949.370.8500

For media inquiries, please contact:
Tamara York
Tamara York Public Relations, LLC
212.967.8300


'/>"/>
SOURCE Aviir
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
2. Aviir, Inc.s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Womens Expo
3. Dr. James Douglas Adds Human Growth Hormone (HGH) Therapy to IVF Protocols for Poor Responding Patients
4. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
5. Douglas Harrington, MD Speaks At American Academy Of Physicians Assistants 2013 Conference In Washington, DC
6. Nominations Open for the Inaugural Harrington Prize for Innovation in Medicine
7. Bunker Hill Community College Student Speaks at 2012 BIO International Convention
8. uBiome CEO Jessica Richman Speaks at TEDMED, Launches Website
9. U.S. Congressman John Campbell Speaks at Southern California TechVoice Breakfast on May 10
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 ... biotechnology company focused on developing aerosolized KL4 surfactant therapies ... webcast (including a slide presentation) at 8:00 AM EST ... the AEROSURF phase 2 clinical program, the recently announced ... business and development activities. To participate in ...
(Date:2/15/2017)... ... February 15, 2017 , ... ... a strategic partnership that puts Diameter Health technology in the hands of Lantana ... allows providers, exchanges, quality improvement and public health entities – all those mining ...
(Date:2/15/2017)... Feb. 15, 2017  Theravance Biopharma, Inc. (NASDAQ: ... announced that it will release financial results for the ... Monday, February 27, 2017. An accompanying ... on February 27, 2017. To participate in the live ... U.S., or (920) 663-6266 for international callers, using the ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):